10-Q: Cara Therapeutics Streamlines Operations After Disappointing Trial Results, Explores Strategic Alternatives

Cara Therapeutics discontinues its notalgia paresthetica program and initiates a strategic review to maximize shareholder value, following disappointing clinical trial results.

Summary

• Cara Therapeutics has decided to discontinue its clinical program for notalgia paresthetica (NP) after oral difelikefalin failed to show meaningful clinical benefit in a recent study.
• The company's board has approved a streamlined operating plan, including a 70% workforce reduction, to explore strategic alternatives.
• This decision follows a previous workforce reduction of up to 50% in January 2024.
• The company's focus has shifted from oral difelikefalin to exploring strategic options to maximize shareholder value.
• Cara Therapeutics has out-licensed the commercialization of KORSUVA injection/Kapruvia for dialysis patients with moderate-to-severe pruritus associated with chronic kidney disease worldwide, excluding Japan and South Korea.
• The company has an accumulated deficit of $735.5 million as of June 30, 2024.
• The company's unrestricted cash and cash equivalents and marketable securities totaled $56.6 million as of June 30, 2024.
• The company has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future.
• The company recognized net losses of $20.0 million and $31.5 million for the three months ended June 30, 2024 and 2023, respectively, and $50.7 million and $58.1 million for the six months ended June 30, 2024 and 2023, respectively.
• The company had net cash used in operating activities of $42.9 million and $55.1 million for the six months ended June 30, 2024 and 2023, respectively.

Sentiment

Score: 3

Explanation: The document reflects a negative sentiment due to the discontinuation of a key clinical program, significant workforce reductions, and ongoing financial losses. The exploration of strategic alternatives also introduces uncertainty about the company's future.

Positives

• The company has completed a streamlined operating plan to reduce costs.
• The company has received regulatory approvals for KORSUVA injection/Kapruvia in multiple countries.
• The company has a partnership with CSL Vifor for commercialization of KORSUVA injection/Kapruvia outside of Japan and South Korea.
• The company has a partnership with Maruishi for commercialization of KORSUVA injection in Japan.

Negatives

• The company's oral difelikefalin program for NP has been discontinued due to lack of efficacy.
• The company has implemented a 70% workforce reduction.
• The company has incurred substantial net losses and negative cash flows from operating activities.
• The company's KORSUVA injection sales in the US have been negatively impacted by changes in CMS reimbursement.
• The company has a significant accumulated deficit of $735.5 million.
• The company's stock price is below $1.00 and the company has received a delisting notice from Nasdaq.

Risks

• The company may not be successful in identifying and implementing any potential strategic alternatives.
• The company may not realize all or any of the anticipated benefits of any strategic transaction.
• The company may be exposed to litigation, including securities class action litigation.
• The company may not be able to regain compliance with Nasdaq listing requirements.
• The company may need additional funding and may be unable to raise capital when needed.
• The company may not be able to successfully complete clinical development, obtain regulatory approvals and commercialize its product candidates.
• The company relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company may experience delays or difficulties in the enrollment of patients in clinical trials.
• The company may not be able to obtain and maintain intellectual property protection for its product candidates.
• The company may be subject to product liability claims.
• The company may be subject to cybersecurity breaches.
• The company may be subject to government investigations or other actions or lawsuits stemming from a failure to be in compliance with healthcare laws or regulations.
• The company may be subject to environmental laws and regulations.
• The company may be subject to changes in tax laws.

Future Outlook

The company expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating plan for at least the next 12 months. The company is exploring strategic alternatives to maximize shareholder value.

Management Comments

• The Board of Directors approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value.
• The company's decision to discontinue the clinical program in NP followed the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP in which oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo.
• The company's decision was not related to any safety or medical issues, or negative regulatory feedback related to the company's NP program.

Industry Context

The biopharmaceutical industry is highly competitive, with many companies developing treatments for pruritus. Cara Therapeutics faces competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. The company's decision to discontinue its NP program and explore strategic alternatives reflects the challenges of drug development and the need to adapt to changing market conditions.

Comparison to Industry Standards

• The discontinuation of the NP program and the subsequent strategic review are not uncommon in the biopharmaceutical industry, where clinical trial failures and shifting market dynamics often lead to strategic pivots.
• The workforce reductions are consistent with industry trends where companies streamline operations to conserve capital after setbacks.
• The company's financial metrics, such as net losses and cash burn, are typical for a clinical-stage biopharmaceutical company, but the lack of revenue growth from KORSUVA injection is a significant concern.
• Compared to other companies with approved products, Cara's revenue from KORSUVA injection is below expectations, highlighting the challenges of commercialization in the pharmaceutical market.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry, but it also introduces risks related to supply chain and quality control.

Management Changes

Related Party Transactions

• CSL Vifor and its affiliates are considered related parties as of June 30, 2024 and December 31, 2023.
• Vifor International owned 7,396,770, or 13.5%, of the company's common stock as of June 30, 2024.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review and potential dilution from future financing.
• Employees have been impacted by significant workforce reductions.
• Customers may experience changes in product availability or support.
• Suppliers and creditors may face uncertainty regarding future business relationships.

Next Steps

• The company will explore strategic alternatives to maximize shareholder value.
• The company will continue to monitor the bid price of its common stock and consider options to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

pruritus, difelikefalin, KORSUVA, Kapruvia, clinical trial, strategic review, workforce reduction, biopharmaceutical, hemodialysis, CKD, licensing, collaboration, royalty, milestone, Nasdaq